---
title: "Evaxion: Buy Rating Reiterated on AI Cancer Vaccine Platform and Upcoming Catalysts; $10 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284259105.md"
description: "Evaxion Biotech received a Buy rating from analyst Debanjana Chatterjee of JonesTrading, maintaining a $10 price target. The rating is based on the company's AI-enabled cancer vaccine platform and upcoming catalysts, including pivotal data for EVX-01 in melanoma. Chatterjee notes strong T-cell responses and a high rate of selected neoantigens, indicating best-in-class potential. He also highlights upcoming events that could enhance Evaxion's value, alongside a manageable cash burn, suggesting an attractive risk-reward profile. H.C. Wainwright also reiterated a Buy rating with a $16 price target."
datetime: "2026-04-27T18:45:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284259105.md)
  - [en](https://longbridge.com/en/news/284259105.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284259105.md)
---

# Evaxion: Buy Rating Reiterated on AI Cancer Vaccine Platform and Upcoming Catalysts; $10 Price Target Unchanged

Evaxion Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on the stock and has a $10.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Debanjana Chatterjee has given his Buy rating due to a combination of factors tied to Evaxion’s AI-enabled cancer vaccine platform and upcoming catalysts. He views the AACR data for EVX-01 in first-line melanoma as demonstrating a highly differentiated profile, with strong, durable T-cell responses and a high rate of accurately selected neoantigens, suggesting best-in-class potential versus conventional approaches.

Chatterjee also highlights a series of near- and medium-term events that could significantly increase Evaxion’s strategic value, including pivotal external readouts in melanoma vaccines, Evaxion’s own 3‑year survival and immunogenicity update for EVX-01, and an expected IND filing for the off‑the‑shelf EVX‑04 AML program. Together with a manageable projected cash burn and the unchanged $10 price target, he sees an attractive risk‑reward skew and room for substantial upside if the data and sector tailwinds materialize as anticipated.

In another report released on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.

### Related Stocks

- [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)
- [Nvidia’s AI Lead Is Back in Focus as Wolfe Research Doubles Down](https://longbridge.com/en/news/286680544.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [TRIPO Launches Tripo Studio AI-Powered 3D Creation Platform](https://longbridge.com/en/news/286665165.md)